Bimatoprost Versus Travoprost at Cairo University

Cairo University

Overview

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months. These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Study Type

OBSERVATIONAL

Conditions

Glaucoma Ocular Hypertension

Eligibility

Sex: ALLMin age: 20 YearsMax age: 72 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Glaucoma and Ocular Hypertension Exclusion Criteria: * Any ocular disease or medication that may raise the intraocular pressure.

Locations (1)

Cairo University

Cairo, Cairo Governorate, Egypt

Outcomes

Primary Outcomes

Percentage of intraocular pressure lowering of bimatoprost versus travoprost.

Secondary Outcomes

Rate of development of complications.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.